X. Bai, J. Findlow, and R. Borrow, Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles, Expert Opin. Biol. Ther, vol.11, pp.969-985, 2001.

S. Bambini, Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus, Vaccine, vol.27, pp.2794-2803, 2009.

C. Brehony, K. A. Jolley, and M. C. Maiden, Multilocus sequence typing for global surveillance of meningococcal disease, FEMS Microbiol. Rev, vol.31, pp.15-26, 2007.

S. Budroni, Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination, Proc. Natl. Acad. Sci. U. S. A, vol.108, pp.4494-4499, 2011.

F. Caron, From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak, Lancet Infect. Dis, vol.11, pp.455-463, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-02083160

. Cdc, Surveillance of invasive bacterial diseases in Europe, Centers for Disease Control and Prevention, 2008.

J. Donnelly, Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of proteinbased vaccines, Proc. Natl. Acad. Sci. U. S. A, vol.107, pp.19490-19495, 2010.

E. J. Feil, Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences, Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.182-187, 2001.

J. Findlow, Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children, Vaccine, vol.23, pp.2623-2627, 2005.

J. Finne, D. Bitter-suermann, C. Goridis, and U. Finne, An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues, J. Immunol, vol.138, pp.4402-4407, 1987.

M. M. Giuliani, A universal vaccine for serogroup B meningococcus, Proc. Natl. Acad. Sci. U. S. A, vol.103, pp.10834-10839, 2006.

D. Goldblatt, Establishment of a new human pneumococcal standard reference serum, 007sp. Clin. Vaccine Immunol, vol.18, pp.1728-1736, 2011.

L. H. Harrison, C. L. Trotter, and M. E. Ramsay, Global epidemiology of meningococcal disease, Vaccine, vol.27, issue.2, pp.51-63, 2009.

Y. Heyden and J. Smeyers-verbeke, Set-up and evaluation of interlaboratory studies, J. Chromatogr. A, vol.1158, pp.158-167, 2007.

J. Holst, Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis, Vaccine, vol.27, issue.2, pp.3-12, 2009.

K. A. Jolley, C. Brehony, and M. C. Maiden, Molecular typing of meningococci: recommendations for target choice and nomenclature, FEMS Microbiol. Rev, vol.31, pp.89-96, 2007.

A. Kapasi, Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays, Clin. Vaccine Immunol, vol.19, pp.64-72, 2012.

L. Lin, A concordance correlation coefficient to evaluate reproducibility, Biometrics, vol.45, pp.255-268, 1989.

M. C. Maiden, Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.3140-3145, 1998.

D. R. Martin, N. Ruijne, L. Mccallum, J. O'hallahan, and P. Oster, The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB, Clin. Vaccine Immunol, vol.13, pp.486-491, 2006.

S. L. Martin, Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine, Vaccine, vol.18, pp.2476-2481, 2000.

C. E. Rose, Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera, Clin. Vaccine Immunol, vol.18, pp.135-142, 2011.

M. Sadarangani and A. J. Pollard, Serogroup B meningococcal vaccines: an unfinished story, Lancet Infect. Dis, vol.10, pp.112-124, 2010.

M. D. Snape, The challenge of post-implementation surveillance for novel meningococcal vaccines, Vaccine, vol.30, issue.2, pp.67-72, 2012.

E. L. Su and M. D. Snape, A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease, Expert Rev. Vaccines, vol.10, pp.575-588, 2011.

L. K. Tan, G. M. Carlone, and R. Borrow, Advances in the development of vaccines against Neisseria meningitidis, N. Engl. J. Med, vol.362, pp.1511-1520, 2010.

J. W. Tappero, Immunogenicity of 2 serogroup B outermembrane protein meningococcal vaccines: a randomized controlled trial in Chile, JAMA, vol.281, pp.1520-1527, 1999.